

Current Clinical Program Portfolio

February 2017
Active Grants

Grant#	Grantee	Program	Project Goal	Indication	Disease Category	Approach	Approved Funds	Therapeutic Cell Type	Cell Source
Neurologic Disorders: Injuries									
SP3A-07552	SP3A-07552 Lebkowski, Asterias Biotherapeutics	Strategic Partnership III	Ph 1/2a	Spinal Cord Injury	Neurologic Injury	Cell Therapy	\$14,323,318	Oligodendrocyte Progenitors	Allogeneic
Neurologic Disorders: Neurodegenerative									
DR2A-05320	DR2A-05320 Svendsen, Cedars-Sinai	Disease Team Therapy Development	Ph 1	ALS (Amyotrophic lateral sclerosis)	Neurodegenerative Disorder	Genetically Modified Cell Therapy	\$17,842,617	NSC or NPC	Allogeneic
Eye Disease									
DR3-07438	DR3-07438 Humayun, USC	Duane Roth Disease Team Therapy Development III	Ph 1	Adult Macular Degeneration	Eye Disease	Cell Therapy, Combination	\$18,922,665	RPE	Allogeneic
LSP1-08235	LSP1-08235 Wang, Cedars-Sinai	Late Stage Preclinical Projects	IND	Retinitis Pigmentosa	Eye Disease	Cell Therapy	\$4,954,514	NPC	Allogeneic
DR2A-05739	DR2A-05739 Klassen, UC Irvine	Disease Team Therapy Development	IND, Ph 1/2a	Retinitis Pigmentosa	Eye Disease	Cell Therapy	\$17,306,668	RPC	Allogeneic
CLIN2-09698	CLIN2-09698 Klassen, Jcyte	Clinical Trial Stage Projects	Ph 2b	Retinitis Pigmentosa	Eye Disease	Cell Therapy	\$8,295,750	RPC	Allogeneic
CLIN1-08686	CLIN1-08686 Deng, UCLA	Clinical Trial Stage Projects	IND	Corneal Blindness	Eye Disease	Cell Therapy	\$4,244,211	Lim	Autologous
Blood Disorders									
CTS1-08231	CTS1-08231 Kohn UCLA	Clinical Trial Stage Projects	Ph 1/2	X-linked Chronic Granulomatous Disease.	Blood Disorder	Genetically Modified Cell Therapy	\$7,402,549	HSC	Autologous
DR3-06945	DR3-06945 Kohn, UCLA	Duane Roth Disease Team Therapy Development III	Ph 1	Sickle Cell Disease	Blood Disorder	Genetically Modified Cell Therapy	\$13,935,441	HSC	Autologous
CLIN2-09339	CLIN2-09339 Kohn, UCLA	Clinical Trial Stage Projects	Ph2	ADA-SCID (severe combined immune deficiency)	Blood Disorder	Genetically Modified Cell Therapy	\$20,000,000	HSC	Autologous
DR2A-05365	DR2A-05365 Shizuru, Stanford	Disease Team Therapy Development	IND, Ph 1/2a	Conditioning regimen for allogeneic HSC transplantation for X-SCID (X- linked severe combined immunodeficiency)	Blood Disorder	Biologic	\$20,000,000	---	---
CLIN1-08363	CLIN1-08363, Puck, UCSF	Late Stage Preclinical Projects	IND	ART-SCID (Artemis-deficient severe combined immunodeficiency)	Blood Disorder	Genetically Modified Cell Therapy	\$4,268,865	HSC	Autologous

Grant#	Grantee	Program	Project Goal	Indication	Disease Category	Approach	Approved Funds	Therapeutic Cell Type	Cell Source
HIV/AIDS									
DR1-06893	DR1-06893 Symonds, Calimmune	Disease Team I	Ph 1/2a	HIV/AIDS	HIV/AIDS	Genetically Modified Cell Therapy	\$8,278,722	HSC	Autologous
CTS1-08231	CTS1-08231 Abedi, UC Davis	Clinical Trial Stage Projects	Ph 1	HIV/AIDS	HIV/AIDS	Genetically Modified Cell Therapy	\$7,402,549	HSC	Autologous
SP3A-07536	SP3A-07536 Zaia, City of Hope	Strategic Partnership III	Ph 1	HIV/AIDS	HIV/AIDS	Genetically Modified Cell Therapy	\$5,583,438	HSC	Autologous
Hematologic Cancers									
DR3-06924	DR3-06924 Kipps, UCSD	Duane Roth Disease Team Therapy Development III	Ph 1	CLL	Hematologic Malignancy	Biologic	\$4,179,600	---	---
CLIN1-08342	CLIN1-08342 Davis, Angiocrine Bioscience	Clinical Trial Stage Projects	IND, Ph 1	Hematologic malignancies including leukemia and lymphoma	Hematologic Malignancy	Cell Therapy	\$3,797,117	Cord blood expanded CD34+ HSPCs and E-CEL ECs	Allogeneic
Solid Cancers									
CTS1-08280	CTS1-08280 Gringeri, Immunocellular Therapeutics	Clinical Trial Stage Projects	Ph 3	Glioblastoma	Solid Tumor	Cell Therapy	\$19,919,449	DC vaccine	Autologous
DR2A-05309	DR2A-05309 Ribas, UCLA	Disease Team Therapy Development	IND, Ph 1	Melanoma	Solid Tumor	Genetically Modified Cell Therapy	\$19,999,563	HSC	Autologous
DR3-07067	DR3-07067 Slamon, UCLA	Duane Roth Disease Team Therapy Development III	Ph 1	Solid Tumor	Solid Tumor	Small Molecule	\$6,924,317	---	---
CLIN2-09577	CLIN2-09577 Chao, 47Inc	Clinical Trial Stage Projects	Ph1b/2	Solid Tumor	Solid Tumor	Biologic	\$10,234,048	---	-
Bone Disorders									
DR2A-05302	DR2A-05302 Lane, UC Davis	Disease Team Therapy Development	Ph 1/2a	Osteoporosis	Bone Disorder	Small Molecule	\$19,999,867	---	---
Cartilage Disorders									
LSP1-08309	LSP1-8309 Schultz, Caliber	Late Stage Preclinical Projects	IND	Osteoarthritis, cartilage injuries	Cartilage Disorder	Small Molecule	\$1,667,832	---	---
Cardiovascular & Vascular Disorders									
DR2A-05735	DR2A-05735 Smith, Capricor Inc.	Disease Team Therapy Development	Ph 2	Heart dysfunction after MI/Chronic heart failure	Cardiovascular Disease	Cell Therapy	\$19,782,136	CDC	Allogeneic
CLIN2-09444	CLIN2-09444 Lewis, Cedars-Sinai	Clinical Trial Stage Projects	Ph1a/2b	Pulmonary Arterial Hypertension	Vascular Disease	Cell Therapy	\$7,354,772	CDC	Allogeneic
DR2A-05394	DR2A-05394 Wu, Stanford	Disease Team Therapy Development	IND	End stage heart failure with LVAD	Cardiovascular Disease	Cell Therapy	\$19,999,899	CM	Allogeneic

Grant#	Grantee	Program	Project Goal	Indication	Disease Category	Approach	Approved Funds	Therapeutic Cell Type	Cell Source
Diabetes & Complications/Metabolic									
AP1-08039	AP1-08039 Foyt, ViaCyte Inc.	Accelerated Pathway I	Comparability Trial	Diabetes: Type 1	Endocrine Disorder	Encapsulated Cell Therapy	\$16,603,160	PCP	Allogeneic
CLIN1-08671	CLIN1-08671, D'Amour, Viacyte	Clinical Trial Stage Projects	IND	Diabetes: Type 1	Endocrine Disorder	Cell Therapy, Combination	\$3,984,164	ESC	Allogeneic
CLIN1-09230	Clin1-09230 Cherqui, UCSD	Clinical Trial Stage Projects	IND	Cystinosis	Cystinosis	Genetically Modified Cell Therapy	\$ 5,273,189	HSC	Autologous
Skeletal Muscle Disorders									
CLIN2-08334	CLIN2-08334 Ascheim, Capricor, Inc.	Clinical Trial Stage Projects	Ph 2	Duchenne muscular dystrophy cardiomyopathy	Skeletal Muscle Disorder	Cell Therapy	\$3,376,259	CDC	Allogeneic
Other Disorders									
DR3-07281	DR3-07281 Belafsky, UC Davis	Duane Roth Disease Team Therapy Development III	IND	Airway stenosis	Respiratory Disorder	Cell Therapy, Combination	\$4,440,000	Bone Marrow Stronal + Airway epithelial	Autologous
CLIN2-08938	CLIN2-08938, Lawson, Humacyte, Inc.	Clinical Trial Stage Projects	Ph 3	Renal dialysis	Endocrine Disorder	Device	\$9,999,528		
CLIN2-09439	CLIN2-09439 Strober, Stanford	Clinical Trial Stage Projects	Ph 1	Transplant tolerance	Immune tolerance, transplant	Cell Therapy	\$5,069,674	HSC	Allogeneic